activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	2470100	CHEMBL1032242	Inhibition of ACVRL1 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL5311	Homo sapiens	INH	%	10.0
	2470100	CHEMBL1032242	Inhibition of ACVRL1 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL5311	Homo sapiens	INH	%	10.0
Not Evaluated	2476594	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167		Activity			CHEMBL5311	Homo sapiens	Activity		
Not Evaluated	2476797	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	NC(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(N)(=O)=O)cc3)c2)cc1		CHEMBL514582		Activity			CHEMBL5311	Homo sapiens	Activity		
Not Evaluated	2478636	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	N#Cc1c(NC(=O)c2ccccc2)sc2c1CCCC2		CHEMBL233000		Activity			CHEMBL5311	Homo sapiens	Activity		
Not Evaluated	2478839	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	O=C1Nc2ccccc2/C1=C/c1ccc[nH]1		CHEMBL86755		Activity			CHEMBL5311	Homo sapiens	Activity		
	2479694	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	N#Cc1ccc(-c2cnc3[nH]cc(NC(=O)c4cccnc4)c3c2)cc1		CHEMBL516312	=	Activity	%	11.7	CHEMBL5311	Homo sapiens	Activity	%	11.7
Active	2480693	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL514409		Activity			CHEMBL5311	Homo sapiens	Activity		
Not Evaluated	2577315	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	CC(=O)c1c(-c2ccncc2)[nH]c(-c2ccncc2)c1C		CHEMBL526901		Activity			CHEMBL5311	Homo sapiens	Activity		
Not Evaluated	2577518	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	NC(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1		CHEMBL511337		Activity			CHEMBL5311	Homo sapiens	Activity		
Not Evaluated	2593520	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878		Activity			CHEMBL5311	Homo sapiens	Activity		
	2593723	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1		CHEMBL249097	=	Activity	%	0.3	CHEMBL5311	Homo sapiens	Activity	%	0.3
	2593989	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNCC1		CHEMBL450519	=	Activity	%	3.3	CHEMBL5311	Homo sapiens	Activity	%	3.3
Not Evaluated	2594932	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL478649		Activity			CHEMBL5311	Homo sapiens	Activity		
Not Evaluated	2595135	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	Cc1ccc(NC(=O)c2cccc(N3CCCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL1964275		Activity			CHEMBL5311	Homo sapiens	Activity		
Not Evaluated	2595201	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(C)(C)C)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL515466		Activity			CHEMBL5311	Homo sapiens	Activity		
Not Evaluated	2596332	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	CN(C)c1ccc(-c2cc3ncccc3c(NCCCCN)n2)cc1		CHEMBL282342		Activity			CHEMBL5311	Homo sapiens	Activity		
	2597601	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1		CHEMBL408019	=	Activity	%	17.45	CHEMBL5311	Homo sapiens	Activity	%	17.45
Not Evaluated	2597804	CHEMBL993458	Binding affinity to human ALK1 at 10 uM relative to control	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454		Activity			CHEMBL5311	Homo sapiens	Activity		
	2896608	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2896609	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2896610	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2896611	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2896612	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2896613	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2896614	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2896615	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2896616	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2896617	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897611	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897612	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Kd	nM	460.0	CHEMBL5311	Homo sapiens	Kd	nM	460.0
	2897613	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897614	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897615	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897616	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897617	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897618	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897619	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897620	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Kd	nM	2900.0	CHEMBL5311	Homo sapiens	Kd	nM	2900.0
	2897621	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897622	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897623	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897624	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897625	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897626	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897627	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897628	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897629	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897630	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897631	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897632	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897633	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897634	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897635	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897636	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897637	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	2897638	CHEMBL1063790	Binding constant for ACVRL1 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	=	Kd	nM	470.0	CHEMBL5311	Homo sapiens	Kd	nM	470.0
	2921447	CHEMBL1057564	Inhibition of ACVRL1 assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	92.0	CHEMBL5311	Homo sapiens	Activity	%	92.0
	3052522	CHEMBL1047773	Residual activity of ACV-RL1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	92.0	CHEMBL5311	Homo sapiens	Residual activity	%	92.0
	3052774	CHEMBL1046507	Residual activity of ACV-RL1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	91.0	CHEMBL5311	Homo sapiens	Residual activity	%	91.0
	3054083	CHEMBL1066601	Residual activity of ACV-RL1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	91.0	CHEMBL5311	Homo sapiens	Residual activity	%	91.0
	3055370	CHEMBL1047773	Residual activity of ACV-RL1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	78.0	CHEMBL5311	Homo sapiens	Residual activity	%	78.0
	3055622	CHEMBL1046507	Residual activity of ACV-RL1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	84.0	CHEMBL5311	Homo sapiens	Residual activity	%	84.0
	3056927	CHEMBL1066601	Residual activity of ACV-RL1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	96.0	CHEMBL5311	Homo sapiens	Residual activity	%	96.0
	3058247	CHEMBL1047773	Residual activity of ACV-RL1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	92.0	CHEMBL5311	Homo sapiens	Residual activity	%	92.0
	3058499	CHEMBL1046507	Residual activity of ACV-RL1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	87.0	CHEMBL5311	Homo sapiens	Residual activity	%	87.0
	3072845	CHEMBL1066601	Residual activity of ACV-RL1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	92.0	CHEMBL5311	Homo sapiens	Residual activity	%	92.0
	3331819	CHEMBL1168586	Inhibition of ACVRL1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL5311	Homo sapiens	INH	%	50.0
	3333234	CHEMBL1168586	Inhibition of ACVRL1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL5311	Homo sapiens	INH	%	50.0
	3334639	CHEMBL1168586	Inhibition of ACVRL1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL5311	Homo sapiens	INH	%	50.0
	3336059	CHEMBL1168586	Inhibition of ACVRL1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL5311	Homo sapiens	INH	%	50.0
	3337445	CHEMBL1168586	Inhibition of ACVRL1 at 1 uM	B	O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1		CHEMBL1163510	<	Inhibition	%	50.0	CHEMBL5311	Homo sapiens	INH	%	50.0
	3337693	CHEMBL1168586	Inhibition of ACVRL1 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1		CHEMBL1163518	<	Inhibition	%	50.0	CHEMBL5311	Homo sapiens	INH	%	50.0
	3339024	CHEMBL1168586	Inhibition of ACVRL1 at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	<	Inhibition	%	50.0	CHEMBL5311	Homo sapiens	INH	%	50.0
	3339280	CHEMBL1168586	Inhibition of ACVRL1 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	<	Inhibition	%	50.0	CHEMBL5311	Homo sapiens	INH	%	50.0
	3340587	CHEMBL1168586	Inhibition of ACVRL1 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL5311	Homo sapiens	INH	%	50.0
	3342003	CHEMBL1168586	Inhibition of ACVRL1 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL5311	Homo sapiens	INH	%	50.0
	3358446	CHEMBL1174060	Inhibition of ACVRL1 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	100.0	CHEMBL5311	Homo sapiens	INH	%	100.0
	3358888	CHEMBL1174060	Inhibition of ACVRL1 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	100.0	CHEMBL5311	Homo sapiens	INH	%	100.0
	3445022	CHEMBL1244716	Binding affinity to ACVRL1	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	2200.0	CHEMBL5311	Homo sapiens	Kd	nM	2200.0
	3448689	CHEMBL1244716	Binding affinity to ACVRL1	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	3449552	CHEMBL1244716	Binding affinity to ACVRL1	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	3449977	CHEMBL1244716	Binding affinity to ACVRL1	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	3450285	CHEMBL1244716	Binding affinity to ACVRL1	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	3450906	CHEMBL1244716	Binding affinity to ACVRL1	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	3451196	CHEMBL1244716	Binding affinity to ACVRL1	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	uM	10.0
	6340971	CHEMBL1827557	Activity of ACVRL1 kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	96.0	CHEMBL5311	Homo sapiens	Activity	%	96.0
	7567172	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7567631	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7568102	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7568570	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7569002	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7569145	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7569605	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7570077	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7571121	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7571578	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Kd	nM	460.0	CHEMBL5311	Homo sapiens	Kd	nM	460.0
	7572054	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	=	Kd	nM	1900.0	CHEMBL5311	Homo sapiens	Kd	nM	1900.0
	7572075	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7572491	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	57.0	CHEMBL5311	Homo sapiens	Kd	nM	57.0
	7573102	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	4200.0	CHEMBL5311	Homo sapiens	Kd	nM	4200.0
	7573559	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7574062	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7574470	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7575080	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7575570	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7576035	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7576443	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	2400.0	CHEMBL5311	Homo sapiens	Kd	nM	2400.0
	7577054	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7577071	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7577549	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7578019	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Kd	nM	2.9	CHEMBL5311	Homo sapiens	Kd	nM	2.9
	7578424	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	=	Kd	nM	470.0	CHEMBL5311	Homo sapiens	Kd	nM	470.0
	7578620	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7579444	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	4500.0	CHEMBL5311	Homo sapiens	Kd	nM	4500.0
	7579918	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7580387	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7580790	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	9500.0	CHEMBL5311	Homo sapiens	Kd	nM	9500.0
	7580978	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7581363	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7581808	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7582279	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7582743	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7583143	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7583324	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7583721	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7584166	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7584637	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7585099	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7585654	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7586062	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7586508	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7586979	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7587615	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7588034	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	2200.0	CHEMBL5311	Homo sapiens	Kd	nM	2200.0
	7588487	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7588967	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7589580	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7590004	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7590471	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7590503	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7590954	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7591553	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7591975	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7592478	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7592931	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7593520	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7593985	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7594458	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7594910	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7595490	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7595964	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7596435	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7596882	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7597018	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7597471	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7597944	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	7598414	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	=	Kd	nM	69.0	CHEMBL5311	Homo sapiens	Kd	nM	69.0
	7598856	CHEMBL1908475	Binding constant for ACVRL1 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	10000.0	CHEMBL5311	Homo sapiens	Kd	nM	10000.0
	10868658	CHEMBL2026332	Inhibition of ALK1	B	Cc1cccc(-n2nccc2-c2ccc3ncn(C)c(=O)c3c2)n1		CHEMBL2024684	>	IC50	nM	5000.0	CHEMBL5311	Homo sapiens	IC50	uM	5.0
	10975666	CHEMBL2064926	Inhibition of Alk1 in presence of 10 uM ATP	B	Nc1ncnn2ccc(C(=O)Nc3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1990583	>	IC50	nM	10000.0	CHEMBL5311	Homo sapiens	IC50	nM	10000.0
	12173746	CHEMBL2212084	Inhibition of ACVRL1 assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	100.0	CHEMBL5311	Homo sapiens	Activity	%	100.0
	13321793	CHEMBL2390526	Inhibition of ALK1 (unknown origin)	B	CN1CCN(c2ccc(-c3cnc4c(-c5ccnc6ccccc56)cnn4c3)cc2)CC1		CHEMBL2385596	<	IC50	nM	5.0	CHEMBL5311	Homo sapiens	IC50	nM	5.0
	13321794	CHEMBL2390526	Inhibition of ALK1 (unknown origin)	B	c1ccc2c(-c3cnn4cc(-c5ccc(N6CCOCC6)cc5)cnc34)ccnc2c1		CHEMBL2385582	<	IC50	nM	5.0	CHEMBL5311	Homo sapiens	IC50	nM	5.0
	13321854	CHEMBL2390526	Inhibition of ALK1 (unknown origin)	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	IC50	nM	106.3	CHEMBL5311	Homo sapiens	IC50	nM	106.3
	13322762	CHEMBL2390526	Inhibition of ALK1 (unknown origin)	B	c1cc(N2CCNCC2)ccc1-c1cnc2c(-c3cn[nH]c3)cnn2c1		CHEMBL2385586	=	IC50	nM	55.0	CHEMBL5311	Homo sapiens	IC50	nM	55.0
	13322764	CHEMBL2390526	Inhibition of ALK1 (unknown origin)	B	COc1ccc(-c2cnc3c(-c4cn[nH]c4)cnn3c2)cc1		CHEMBL2385600	=	IC50	nM	52.4	CHEMBL5311	Homo sapiens	IC50	nM	52.4
	13322766	CHEMBL2390526	Inhibition of ALK1 (unknown origin)	B	COc1ccc(-c2cnc3c(-c4cccc5ncccc45)cnn3c2)cc1		CHEMBL502351	=	IC50	nM	46.0	CHEMBL5311	Homo sapiens	IC50	nM	46.0
	13322769	CHEMBL2390526	Inhibition of ALK1 (unknown origin)	B	c1cc(N2CCOCC2)ccc1-c1cnc2c(-c3cn[nH]c3)cnn2c1		CHEMBL2385579	=	IC50	nM	42.1	CHEMBL5311	Homo sapiens	IC50	nM	42.1
	13322776	CHEMBL2390526	Inhibition of ALK1 (unknown origin)	B	CC(C)Oc1ccc(-c2cnc3c(-c4ccnc5ccccc45)cnn3c2)cc1		CHEMBL2385597	=	IC50	nM	27.0	CHEMBL5311	Homo sapiens	IC50	nM	27.0
	13322777	CHEMBL2390526	Inhibition of ALK1 (unknown origin)	B	COc1ccc(-c2cnc3c(-c4ccnc5ccccc45)cnn3c2)cc1		CHEMBL511563	=	IC50	nM	26.5	CHEMBL5311	Homo sapiens	IC50	nM	26.5
	13322786	CHEMBL2390526	Inhibition of ALK1 (unknown origin)	B	c1cc(-c2cnn3cc(-c4ccc(N5CCNCC5)cc4)cnc23)c2cccnc2c1		CHEMBL2385591	=	IC50	nM	14.4	CHEMBL5311	Homo sapiens	IC50	nM	14.4
	13322788	CHEMBL2390526	Inhibition of ALK1 (unknown origin)	B	c1ccc2c(-c3cnn4cc(-c5ccc(N6CCNCC6)cc5)cnc34)ccnc2c1		CHEMBL513147	=	IC50	nM	13.3	CHEMBL5311	Homo sapiens	IC50	nM	13.3
	13439904	CHEMBL2428333	Competitive binding affinity to ACVRL1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL5311	Homo sapiens	INH	%	50.0
	13445410	CHEMBL2428333	Competitive binding affinity to ACVRL1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1		CHEMBL2425644	<	Inhibition	%	50.0	CHEMBL5311	Homo sapiens	INH	%	50.0
	13448469	CHEMBL2428333	Competitive binding affinity to ACVRL1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	<	Inhibition	%	50.0	CHEMBL5311	Homo sapiens	INH	%	50.0
	13451724	CHEMBL2428333	Competitive binding affinity to ACVRL1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	<	Inhibition	%	50.0	CHEMBL5311	Homo sapiens	INH	%	50.0
	14659679	CHEMBL3268802	Inhibition of ALK1 (unknown origin) by radioisotopic assay	B	Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1		CHEMBL3260567	>	IC50	nM	10000.0	CHEMBL5311	Homo sapiens	IC50	uM	10.0
	14659680	CHEMBL3268802	Inhibition of ALK1 (unknown origin) by radioisotopic assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	850.0	CHEMBL5311	Homo sapiens	IC50	uM	0.85
	15055363	CHEMBL3380495	Inhibition of ACVRL1 (unknown origin) assessed as residual activity at 1 uM by radiometric protein kinase assay	B	COc1cc(-c2c[nH]c(=O)c(-c3cc(OC)c(OC)c(OC)c3)n2)ccc1O		CHEMBL3358999	=	Activity	%	16.0	CHEMBL5311	Homo sapiens	Activity	%	16.0
	15060876	CHEMBL3365514	Inhibition of ALK1 (unknown origin) expressed in HEK293T cells after 30 mins by luciferase reporter gene assay	B	COc1cc(-c2cc(-c3ccc(N4CCNCC4)cc3)cnc2C)cc(OC)c1OC		CHEMBL3341789	=	IC50	nM	27.0	CHEMBL5311	Homo sapiens	IC50	nM	27.0
	15756115	CHEMBL3631719	Inhibition of ALK1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	96.19	CHEMBL5311	Homo sapiens	INH	%	96.19
	15757710	CHEMBL3631719	Inhibition of ALK1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	3.54	CHEMBL5311	Homo sapiens	INH	%	3.54
	15757984	CHEMBL3631719	Inhibition of ALK1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	28.2	CHEMBL5311	Homo sapiens	INH	%	28.2
263032	16271497	CHEMBL3705956	In Vitro Kinase Activity Assay: Compounds to be tested were dissolved in 100% DMSO in a range of concentrations from 10-8 to 10-3 M including negative control (DMSO), then diluted with Kinase Buffer (50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, and 2 mM DTT, added fresh) to 4x the final concentration. The final curve included 11 concentrations (10-11 to 10-5 M) plus negative control DMSO tested in triplicate.Kinase and ATP concentrations necessary for optimal activity were determined in separate experiments. (Table 2). Briefly, increasing concentrations of kinase were incubated in a fixed concentration of ATP (200 uM) in Kinase Buffer to determine maximal activity at various time points (30-120 min). The concentration of kinase that resulted in maximal activity with the shortest incubation time was then incubated in Kinase Buffer with increasing concentrations of ATP.	B	C[C@@H](Cc1c(F)c(F)cc(F)c1F)Nc1cc[nH]c(=O)c1-c1nc2cc3c(cc2[nH]1)CN(CCN(C)C)C3=O		CHEMBL3671311	=	IC50	nM	4.701	CHEMBL5311	Homo sapiens	IC50	nM	4.701
263042	16273872	CHEMBL3705956	In Vitro Kinase Activity Assay: Compounds to be tested were dissolved in 100% DMSO in a range of concentrations from 10-8 to 10-3 M including negative control (DMSO), then diluted with Kinase Buffer (50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, and 2 mM DTT, added fresh) to 4x the final concentration. The final curve included 11 concentrations (10-11 to 10-5 M) plus negative control DMSO tested in triplicate.Kinase and ATP concentrations necessary for optimal activity were determined in separate experiments. (Table 2). Briefly, increasing concentrations of kinase were incubated in a fixed concentration of ATP (200 uM) in Kinase Buffer to determine maximal activity at various time points (30-120 min). The concentration of kinase that resulted in maximal activity with the shortest incubation time was then incubated in Kinase Buffer with increasing concentrations of ATP.	B	Cc1c2c(cc3[nH]c(-c4c(NC(C)Cc5c(F)c(F)cc(F)c5F)cc[nH]c4=O)nc13)C(=O)N(C1CCN(C)CC1)C2=O		CHEMBL3671321	=	IC50	nM	231.3	CHEMBL5311	Homo sapiens	IC50	nM	231.3
263038	16274070	CHEMBL3705956	In Vitro Kinase Activity Assay: Compounds to be tested were dissolved in 100% DMSO in a range of concentrations from 10-8 to 10-3 M including negative control (DMSO), then diluted with Kinase Buffer (50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, and 2 mM DTT, added fresh) to 4x the final concentration. The final curve included 11 concentrations (10-11 to 10-5 M) plus negative control DMSO tested in triplicate.Kinase and ATP concentrations necessary for optimal activity were determined in separate experiments. (Table 2). Briefly, increasing concentrations of kinase were incubated in a fixed concentration of ATP (200 uM) in Kinase Buffer to determine maximal activity at various time points (30-120 min). The concentration of kinase that resulted in maximal activity with the shortest incubation time was then incubated in Kinase Buffer with increasing concentrations of ATP.	B	CC(Cc1cc(F)ccc1F)Nc1cc[nH]c(=O)c1-c1nc2cc3c(cc2[nH]1)C(=O)N(CCN(C)C)C3=O		CHEMBL3671317	=	IC50	nM	38.86	CHEMBL5311	Homo sapiens	IC50	nM	38.86
263033	16280171	CHEMBL3705956	In Vitro Kinase Activity Assay: Compounds to be tested were dissolved in 100% DMSO in a range of concentrations from 10-8 to 10-3 M including negative control (DMSO), then diluted with Kinase Buffer (50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, and 2 mM DTT, added fresh) to 4x the final concentration. The final curve included 11 concentrations (10-11 to 10-5 M) plus negative control DMSO tested in triplicate.Kinase and ATP concentrations necessary for optimal activity were determined in separate experiments. (Table 2). Briefly, increasing concentrations of kinase were incubated in a fixed concentration of ATP (200 uM) in Kinase Buffer to determine maximal activity at various time points (30-120 min). The concentration of kinase that resulted in maximal activity with the shortest incubation time was then incubated in Kinase Buffer with increasing concentrations of ATP.	B	CC(Cc1cc(F)ccc1F)Nc1cc[nH]c(=O)c1-c1nc2cc3c(cc2[nH]1)C(=O)N(C1CCN(C)CC1)C3=O		CHEMBL3671312	=	IC50	nM	15.11	CHEMBL5311	Homo sapiens	IC50	nM	15.11
263036	16299060	CHEMBL3705956	In Vitro Kinase Activity Assay: Compounds to be tested were dissolved in 100% DMSO in a range of concentrations from 10-8 to 10-3 M including negative control (DMSO), then diluted with Kinase Buffer (50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, and 2 mM DTT, added fresh) to 4x the final concentration. The final curve included 11 concentrations (10-11 to 10-5 M) plus negative control DMSO tested in triplicate.Kinase and ATP concentrations necessary for optimal activity were determined in separate experiments. (Table 2). Briefly, increasing concentrations of kinase were incubated in a fixed concentration of ATP (200 uM) in Kinase Buffer to determine maximal activity at various time points (30-120 min). The concentration of kinase that resulted in maximal activity with the shortest incubation time was then incubated in Kinase Buffer with increasing concentrations of ATP.	B	COC1c2cc3[nH]c(-c4c(NC(C)Cc5c(F)c(F)cc(F)c5F)cc[nH]c4=O)nc3cc2C(=O)N1c1cccnc1		CHEMBL3671315	=	IC50	nM	174.4	CHEMBL5311	Homo sapiens	IC50	nM	174.4
263039	16305225	CHEMBL3705956	In Vitro Kinase Activity Assay: Compounds to be tested were dissolved in 100% DMSO in a range of concentrations from 10-8 to 10-3 M including negative control (DMSO), then diluted with Kinase Buffer (50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, and 2 mM DTT, added fresh) to 4x the final concentration. The final curve included 11 concentrations (10-11 to 10-5 M) plus negative control DMSO tested in triplicate.Kinase and ATP concentrations necessary for optimal activity were determined in separate experiments. (Table 2). Briefly, increasing concentrations of kinase were incubated in a fixed concentration of ATP (200 uM) in Kinase Buffer to determine maximal activity at various time points (30-120 min). The concentration of kinase that resulted in maximal activity with the shortest incubation time was then incubated in Kinase Buffer with increasing concentrations of ATP.	B	CC(Cc1cc(F)ccc1F)Nc1cc[nH]c(=O)c1-c1nc2cc3c(cc2[nH]1)C(=O)N(CCN(C)C)C3		CHEMBL3671318	=	IC50	nM	9.157	CHEMBL5311	Homo sapiens	IC50	nM	9.157
263037	16306187	CHEMBL3705956	In Vitro Kinase Activity Assay: Compounds to be tested were dissolved in 100% DMSO in a range of concentrations from 10-8 to 10-3 M including negative control (DMSO), then diluted with Kinase Buffer (50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, and 2 mM DTT, added fresh) to 4x the final concentration. The final curve included 11 concentrations (10-11 to 10-5 M) plus negative control DMSO tested in triplicate.Kinase and ATP concentrations necessary for optimal activity were determined in separate experiments. (Table 2). Briefly, increasing concentrations of kinase were incubated in a fixed concentration of ATP (200 uM) in Kinase Buffer to determine maximal activity at various time points (30-120 min). The concentration of kinase that resulted in maximal activity with the shortest incubation time was then incubated in Kinase Buffer with increasing concentrations of ATP.	B	C[C@@H](Cc1c(F)c(F)cc(F)c1F)Nc1cc[nH]c(=O)c1-c1nc2cc3c(cc2[nH]1)C(=O)N(c1ccc(F)nc1)C3=O		CHEMBL3671316	>	IC50	nM	10000.0	CHEMBL5311	Homo sapiens	IC50	nM	10000.0
263030	16310932	CHEMBL3705956	In Vitro Kinase Activity Assay: Compounds to be tested were dissolved in 100% DMSO in a range of concentrations from 10-8 to 10-3 M including negative control (DMSO), then diluted with Kinase Buffer (50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, and 2 mM DTT, added fresh) to 4x the final concentration. The final curve included 11 concentrations (10-11 to 10-5 M) plus negative control DMSO tested in triplicate.Kinase and ATP concentrations necessary for optimal activity were determined in separate experiments. (Table 2). Briefly, increasing concentrations of kinase were incubated in a fixed concentration of ATP (200 uM) in Kinase Buffer to determine maximal activity at various time points (30-120 min). The concentration of kinase that resulted in maximal activity with the shortest incubation time was then incubated in Kinase Buffer with increasing concentrations of ATP.	B	C[C@@H](Cc1c(F)c(F)cc(F)c1F)Nc1cc[nH]c(=O)c1-c1nc2cc3c(cc2[nH]1)CN(C1CCN(C)CC1)C3=O		CHEMBL3671309	=	IC50	nM	9.812	CHEMBL5311	Homo sapiens	IC50	nM	9.812
263040	16317081	CHEMBL3705956	In Vitro Kinase Activity Assay: Compounds to be tested were dissolved in 100% DMSO in a range of concentrations from 10-8 to 10-3 M including negative control (DMSO), then diluted with Kinase Buffer (50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, and 2 mM DTT, added fresh) to 4x the final concentration. The final curve included 11 concentrations (10-11 to 10-5 M) plus negative control DMSO tested in triplicate.Kinase and ATP concentrations necessary for optimal activity were determined in separate experiments. (Table 2). Briefly, increasing concentrations of kinase were incubated in a fixed concentration of ATP (200 uM) in Kinase Buffer to determine maximal activity at various time points (30-120 min). The concentration of kinase that resulted in maximal activity with the shortest incubation time was then incubated in Kinase Buffer with increasing concentrations of ATP.	B	Cc1c2c(cc3nc(-c4c(NC(C)Cc5c(F)c(F)cc(F)c5F)cc[nH]c4=O)[nH]c13)CN(C1CCN(C)CC1)C2=O		CHEMBL3671319	=	IC50	nM	23.7	CHEMBL5311	Homo sapiens	IC50	nM	23.7
263029	16323029	CHEMBL3705956	In Vitro Kinase Activity Assay: Compounds to be tested were dissolved in 100% DMSO in a range of concentrations from 10-8 to 10-3 M including negative control (DMSO), then diluted with Kinase Buffer (50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, and 2 mM DTT, added fresh) to 4x the final concentration. The final curve included 11 concentrations (10-11 to 10-5 M) plus negative control DMSO tested in triplicate.Kinase and ATP concentrations necessary for optimal activity were determined in separate experiments. (Table 2). Briefly, increasing concentrations of kinase were incubated in a fixed concentration of ATP (200 uM) in Kinase Buffer to determine maximal activity at various time points (30-120 min). The concentration of kinase that resulted in maximal activity with the shortest incubation time was then incubated in Kinase Buffer with increasing concentrations of ATP.	B	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	=	IC50	nM	1.361	CHEMBL5311	Homo sapiens	IC50	nM	1.361
263041	16328396	CHEMBL3705956	In Vitro Kinase Activity Assay: Compounds to be tested were dissolved in 100% DMSO in a range of concentrations from 10-8 to 10-3 M including negative control (DMSO), then diluted with Kinase Buffer (50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, and 2 mM DTT, added fresh) to 4x the final concentration. The final curve included 11 concentrations (10-11 to 10-5 M) plus negative control DMSO tested in triplicate.Kinase and ATP concentrations necessary for optimal activity were determined in separate experiments. (Table 2). Briefly, increasing concentrations of kinase were incubated in a fixed concentration of ATP (200 uM) in Kinase Buffer to determine maximal activity at various time points (30-120 min). The concentration of kinase that resulted in maximal activity with the shortest incubation time was then incubated in Kinase Buffer with increasing concentrations of ATP.	B	Cc1c2c(cc3[nH]c(-c4c(NC(C)Cc5c(F)c(F)cc(F)c5F)cc[nH]c4=O)nc13)C(=O)N(C1CCN(C)CC1)C2		CHEMBL3671320	=	IC50	nM	14.59	CHEMBL5311	Homo sapiens	IC50	nM	14.59
263031	16334727	CHEMBL3705956	In Vitro Kinase Activity Assay: Compounds to be tested were dissolved in 100% DMSO in a range of concentrations from 10-8 to 10-3 M including negative control (DMSO), then diluted with Kinase Buffer (50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, and 2 mM DTT, added fresh) to 4x the final concentration. The final curve included 11 concentrations (10-11 to 10-5 M) plus negative control DMSO tested in triplicate.Kinase and ATP concentrations necessary for optimal activity were determined in separate experiments. (Table 2). Briefly, increasing concentrations of kinase were incubated in a fixed concentration of ATP (200 uM) in Kinase Buffer to determine maximal activity at various time points (30-120 min). The concentration of kinase that resulted in maximal activity with the shortest incubation time was then incubated in Kinase Buffer with increasing concentrations of ATP.	B	C[C@@H](Cc1c(F)c(F)cc(F)c1F)Nc1cc[nH]c(=O)c1-c1nc2cc3c(cc2[nH]1)C(=O)N(CCN(C)C)C3=O		CHEMBL3671310	=	IC50	nM	14.03	CHEMBL5311	Homo sapiens	IC50	nM	14.03
263035	16337542	CHEMBL3705956	In Vitro Kinase Activity Assay: Compounds to be tested were dissolved in 100% DMSO in a range of concentrations from 10-8 to 10-3 M including negative control (DMSO), then diluted with Kinase Buffer (50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, and 2 mM DTT, added fresh) to 4x the final concentration. The final curve included 11 concentrations (10-11 to 10-5 M) plus negative control DMSO tested in triplicate.Kinase and ATP concentrations necessary for optimal activity were determined in separate experiments. (Table 2). Briefly, increasing concentrations of kinase were incubated in a fixed concentration of ATP (200 uM) in Kinase Buffer to determine maximal activity at various time points (30-120 min). The concentration of kinase that resulted in maximal activity with the shortest incubation time was then incubated in Kinase Buffer with increasing concentrations of ATP.	B	C[C@@H](Cc1c(F)c(F)cc(F)c1F)Nc1cc[nH]c(=O)c1-c1nc2cc3c(cc2[nH]1)C(O)N(c1cccnc1)C3=O		CHEMBL3671314	=	IC50	nM	15.18	CHEMBL5311	Homo sapiens	IC50	nM	15.18
263034	16339932	CHEMBL3705956	In Vitro Kinase Activity Assay: Compounds to be tested were dissolved in 100% DMSO in a range of concentrations from 10-8 to 10-3 M including negative control (DMSO), then diluted with Kinase Buffer (50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, and 2 mM DTT, added fresh) to 4x the final concentration. The final curve included 11 concentrations (10-11 to 10-5 M) plus negative control DMSO tested in triplicate.Kinase and ATP concentrations necessary for optimal activity were determined in separate experiments. (Table 2). Briefly, increasing concentrations of kinase were incubated in a fixed concentration of ATP (200 uM) in Kinase Buffer to determine maximal activity at various time points (30-120 min). The concentration of kinase that resulted in maximal activity with the shortest incubation time was then incubated in Kinase Buffer with increasing concentrations of ATP.	B	C[C@@H](Cc1c(F)c(F)cc(F)c1F)Nc1cc[nH]c(=O)c1-c1nc2cc3c(cc2[nH]1)C(=O)N(c1cccnc1)C3=O		CHEMBL3671313	=	IC50	nM	47.3	CHEMBL5311	Homo sapiens	IC50	nM	47.3
	16431727	CHEMBL3749735	Inhibition of human ALK1 using poly[Glu:Tyr] (4:1) as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL5311	Homo sapiens	IC50	uM	10.0
	16575572	CHEMBL3802208	Inhibition of human ALK1 at 10 uM measured after 40 mins by scintillation counting	B	CNC(=O)c1cc(Oc2ccc3nc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)sc3c2)ccn1		CHEMBL3797601	<	Inhibition	%	40.0	CHEMBL5311	Homo sapiens	INH	%	40.0
	16613765	CHEMBL3816558	Inhibition of human ALK1 at 1 uM using casein as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	-8.0	CHEMBL5311	Homo sapiens	INH	%	-8.0
	16627858	CHEMBL3820157	Inhibition of ALK1 (unknown origin)	B	CC(=O)Nc1cc(Nc2c(Cl)ccc3c2OCO3)ccn1		CHEMBL3818628	=	IC50	nM	48.0	CHEMBL5311	Homo sapiens	IC50	uM	0.048
	16627859	CHEMBL3820157	Inhibition of ALK1 (unknown origin)	B	CCC(=O)Nc1cc(Nc2c(Cl)ccc3c2OCO3)ccn1		CHEMBL3818920	=	IC50	nM	40.0	CHEMBL5311	Homo sapiens	IC50	uM	0.04
	16627860	CHEMBL3820157	Inhibition of ALK1 (unknown origin)	B	CC(C)C(=O)Nc1cc(Nc2c(Cl)ccc3c2OCO3)ccn1		CHEMBL3818832	=	IC50	nM	800.0	CHEMBL5311	Homo sapiens	IC50	uM	0.8
	16627861	CHEMBL3820157	Inhibition of ALK1 (unknown origin)	B	O=C(Nc1cc(Nc2c(Cl)ccc3c2OCO3)ccn1)C1CC1		CHEMBL3819089	=	IC50	nM	17.0	CHEMBL5311	Homo sapiens	IC50	uM	0.017
	16627862	CHEMBL3820157	Inhibition of ALK1 (unknown origin)	B	O=C(Nc1cc(Nc2c(Cl)ccc3c2OCO3)ccn1)C1CCC1		CHEMBL3819276	=	IC50	nM	230.0	CHEMBL5311	Homo sapiens	IC50	uM	0.23
	16627863	CHEMBL3820157	Inhibition of ALK1 (unknown origin)	B	O=C(Nc1cc(Nc2c(Cl)ccc3c2OCO3)ccn1)C1CCCC1		CHEMBL3817884	=	IC50	nM	940.0	CHEMBL5311	Homo sapiens	IC50	uM	0.94
	16627864	CHEMBL3820157	Inhibition of ALK1 (unknown origin)	B	O=C(Nc1cc(Nc2c(Cl)ccc3c2OCO3)ccn1)c1ccccc1		CHEMBL3818797	=	IC50	nM	340.0	CHEMBL5311	Homo sapiens	IC50	uM	0.34
	16627865	CHEMBL3820157	Inhibition of ALK1 (unknown origin)	B	O=C(Nc1cc(Nc2ccccc2Cl)ccn1)C1CC1		CHEMBL3818666	=	IC50	nM	4600.0	CHEMBL5311	Homo sapiens	IC50	uM	4.6
	16627866	CHEMBL3820157	Inhibition of ALK1 (unknown origin)	B	O=C(Nc1cc(Nc2cccc3c2OCO3)ccn1)C1CC1		CHEMBL3819259	=	IC50	nM	120.0	CHEMBL5311	Homo sapiens	IC50	uM	0.12
	16628438	CHEMBL3820157	Inhibition of ALK1 (unknown origin)	B	O=C(Nc1cc(Nc2ccccc2)ccn1)C1CC1		CHEMBL3818030	=	IC50	nM	2300.0	CHEMBL5311	Homo sapiens	IC50	uM	2.3
	16628439	CHEMBL3820157	Inhibition of ALK1 (unknown origin)	B	O=C(Nc1cc(Nc2ccncc2)ccn1)C1CC1		CHEMBL3818411	=	IC50	nM	1000.0	CHEMBL5311	Homo sapiens	IC50	uM	1.0
	16628440	CHEMBL3820157	Inhibition of ALK1 (unknown origin)	B	O=C(Nc1cc(Nc2c(Cl)cnc3c2OCO3)ccn1)C1CC1		CHEMBL3818173	=	IC50	nM	4.0	CHEMBL5311	Homo sapiens	IC50	uM	0.004
	16628441	CHEMBL3820157	Inhibition of ALK1 (unknown origin)	B	CN(c1ccnc(NC(=O)C2CC2)c1)c1c(Cl)cnc2c1OCO2		CHEMBL3818656	=	IC50	nM	26.0	CHEMBL5311	Homo sapiens	IC50	uM	0.026
	16628442	CHEMBL3820158	Inhibition of ALK1 in HMEC-1 assessed as translocation of pSMAD1/5	B	CC(=O)Nc1cc(Nc2c(Cl)ccc3c2OCO3)ccn1		CHEMBL3818628	=	IC50	nM	3600.0	CHEMBL5311	Homo sapiens	IC50	uM	3.6
	16628443	CHEMBL3820158	Inhibition of ALK1 in HMEC-1 assessed as translocation of pSMAD1/5	B	CCC(=O)Nc1cc(Nc2c(Cl)ccc3c2OCO3)ccn1		CHEMBL3818920	=	IC50	nM	980.0	CHEMBL5311	Homo sapiens	IC50	uM	0.98
	16628444	CHEMBL3820158	Inhibition of ALK1 in HMEC-1 assessed as translocation of pSMAD1/5	B	O=C(Nc1cc(Nc2c(Cl)ccc3c2OCO3)ccn1)C1CC1		CHEMBL3819089	=	IC50	nM	240.0	CHEMBL5311	Homo sapiens	IC50	uM	0.24
	16628445	CHEMBL3820158	Inhibition of ALK1 in HMEC-1 assessed as translocation of pSMAD1/5	B	O=C(Nc1cc(Nc2cccc3c2OCO3)ccn1)C1CC1		CHEMBL3819259	=	IC50	nM	2300.0	CHEMBL5311	Homo sapiens	IC50	uM	2.3
	16628446	CHEMBL3820158	Inhibition of ALK1 in HMEC-1 assessed as translocation of pSMAD1/5	B	O=C(Nc1cc(Nc2ccncc2)ccn1)C1CC1		CHEMBL3818411	=	IC50	nM	3800.0	CHEMBL5311	Homo sapiens	IC50	uM	3.8
	16628447	CHEMBL3820158	Inhibition of ALK1 in HMEC-1 assessed as translocation of pSMAD1/5	B	O=C(Nc1cc(Nc2c(Cl)cnc3c2OCO3)ccn1)C1CC1		CHEMBL3818173	=	IC50	nM	45.0	CHEMBL5311	Homo sapiens	IC50	uM	0.045
	16628448	CHEMBL3820158	Inhibition of ALK1 in HMEC-1 assessed as translocation of pSMAD1/5	B	CN(c1ccnc(NC(=O)C2CC2)c1)c1c(Cl)cnc2c1OCO2		CHEMBL3818656	=	IC50	nM	320.0	CHEMBL5311	Homo sapiens	IC50	uM	0.32
	16628460	CHEMBL3820163	Inhibition of human recombinant GST-tagged ALK1 expressed in baculovirus by FRET assay	B	O=C(Nc1cc(Nc2c(Cl)cnc3c2OCO3)ccn1)C1CC1		CHEMBL3818173	=	IC50	nM	1.1	CHEMBL5311	Homo sapiens	IC50	nM	1.1
198895	17602396	CHEMBL3706167	"Radiometric Assay: ALKl (Invitrogen, Carlsbad, CA, USA) kinase activity was measured at ProQinase GmbH ( Freiburg. Germany) in a radiometric assay using gamma-33P-ATP and casein (Sigma, St. Louis, MO, USA) as substrate in 96-weli PerkinElmer FlashPlates (Boston, MA, USA). The compounds were tested at 10 concentrations in the range of 1 x 10""4 M to 3 x 10""9 M in a total volume of 50 ul with a finalDMSO concentration of 1 % each. The assay components were mixed in the order: 20 ul assay buffer (70 mM HEPES-NaOH, pi I 7.5. 3 mM MgCl2, 3 mM MnCl2, 2uM sodium orthovanadate, 1.2 mM DTT); - 5ul gamma-33P-ATP (1.0ug/50ug in water, approx. 6 x10E+5 cpm per well); 5 ul test compound solution (in 10% DMSO);10 ul substrate (200 ug/ml, 1.0ug/50ml final concentration) / enzyme (4 ug/ml, 20 ng/50ul = 5.5 nM final concentration) solution (1 : 1 mixture)."	B	Nc1ncnn2c(N3CCOCC3)cc(-c3ccc(CO)c(F)c3)c12		CHEMBL3668002	=	IC50	nM	25.0	CHEMBL5311	Homo sapiens	IC50	nM	25.0
303449	17684310	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	CCCc1cc(-c2ccc(CO)cc2)c2c(N)ncnn12		CHEMBL3667963	=	IC50	nM	2.0	CHEMBL5311	Homo sapiens	IC50	nM	2.0
303450	17684311	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	CCCc1cc(-c2cc(F)c(CO)c(F)c2)c2c(N)ncnn12		CHEMBL3667964	=	IC50	nM	2.8	CHEMBL5311	Homo sapiens	IC50	nM	2.8
303451	17684312	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(CCCO)cc(-c3ccc(CO)cc3)c12		CHEMBL3667965	=	IC50	nM	4.0	CHEMBL5311	Homo sapiens	IC50	nM	4.0
303452	17684313	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(CCCCO)cc(-c3ccc(CO)cc3)c12		CHEMBL3667966	=	IC50	nM	1.0	CHEMBL5311	Homo sapiens	IC50	nM	1.0
303453	17684314	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(C(O)C3CC3)cc(-c3cc(F)c(CO)c(F)c3)c12		CHEMBL3667967	=	IC50	nM	1.3	CHEMBL5311	Homo sapiens	IC50	nM	1.3
303454	17684315	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(C(O)C3CCOCC3)cc(-c3cc(F)c(CO)c(F)c3)c12		CHEMBL3667968	=	IC50	nM	40.0	CHEMBL5311	Homo sapiens	IC50	nM	40.0
303455	17684316	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c1c(-c1cc(F)c(CO)c(F)c1)cc2[C@H]1CC[C@H](O)CC1		CHEMBL3667969	=	IC50	nM	2.0	CHEMBL5311	Homo sapiens	IC50	nM	2.0
303456	17684317	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(C3CCNC3)cc(-c3cc(F)c(CO)c(F)c3)c12		CHEMBL3667970	=	IC50	nM	4.4	CHEMBL5311	Homo sapiens	IC50	nM	4.4
303457	17684318	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(C3(O)CCCNC3)cc(-c3cc(F)c(CO)c(F)c3)c12		CHEMBL3667971	=	IC50	nM	5.7	CHEMBL5311	Homo sapiens	IC50	nM	5.7
303458	17684319	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(C3CCNCC3)cc(-c3ccc(CO)cc3)c12		CHEMBL3667972	=	IC50	nM	8.0	CHEMBL5311	Homo sapiens	IC50	nM	8.0
303459	17684320	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c([C@@H]3CCCNC3)cc(-c3cc(F)c(CO)c(F)c3)c12		CHEMBL3667973	=	IC50	nM	1.9	CHEMBL5311	Homo sapiens	IC50	nM	1.9
303460	17684321	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c([C@H]3CCCNC3)cc(-c3cc(F)c(CO)c(F)c3)c12		CHEMBL3667974	=	IC50	nM	5.9	CHEMBL5311	Homo sapiens	IC50	nM	5.9
303461	17684322	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Cc1nc(-c2cc(-c3ccc(CO)cc3)c3c(N)ncnn23)cs1		CHEMBL3667975	=	IC50	nM	4.0	CHEMBL5311	Homo sapiens	IC50	nM	4.0
303462	17684323	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Cc1nc(-c2cc(-c3cc(F)c(CO)c(F)c3)c3c(N)ncnn23)cs1		CHEMBL3667976	=	IC50	nM	5.3	CHEMBL5311	Homo sapiens	IC50	nM	5.3
303463	17684324	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	CCc1nc(-c2cc(-c3ccc(CO)cc3)c3c(N)ncnn23)cs1		CHEMBL3667977	=	IC50	nM	60.0	CHEMBL5311	Homo sapiens	IC50	nM	60.0
303464	17684325	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	CCc1nc(-c2cc(-c3cc(F)c(CO)c(F)c3)c3c(N)ncnn23)cs1		CHEMBL3667978	=	IC50	nM	2.6	CHEMBL5311	Homo sapiens	IC50	nM	2.6
303465	17684326	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1nc(-c2cc(-c3ccc(CO)cc3)c3c(N)ncnn23)cs1		CHEMBL3667979	=	IC50	nM	2.0	CHEMBL5311	Homo sapiens	IC50	nM	2.0
303466	17684327	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(CN3CCNCC3)cc(-c3ccc(CO)cc3)c12		CHEMBL3667980	=	IC50	nM	80.0	CHEMBL5311	Homo sapiens	IC50	nM	80.0
303467	17684328	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(CN3CCOCC3)cc(-c3ccc(CO)cc3)c12		CHEMBL3667981	=	IC50	nM	19.0	CHEMBL5311	Homo sapiens	IC50	nM	19.0
303468	17684329	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(CN3CCOCC3)cc(-c3cc(F)c(CO)c(F)c3)c12		CHEMBL3667982	=	IC50	nM	30.0	CHEMBL5311	Homo sapiens	IC50	nM	30.0
303469	17684330	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(CN3CCOCC3)cc(-c3ccc(CO)c(Cl)c3)c12		CHEMBL3667983	=	IC50	nM	17.0	CHEMBL5311	Homo sapiens	IC50	nM	17.0
303470	17684331	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Cc1cc(-c2cc(CN3CCOCC3)n3ncnc(N)c23)ccc1CO		CHEMBL3667984	=	IC50	nM	30.0	CHEMBL5311	Homo sapiens	IC50	nM	30.0
303471	17684332	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(CN3CCOCC3)cc(-c3ccc(CO)nc3)c12		CHEMBL3667985	=	IC50	nM	140.0	CHEMBL5311	Homo sapiens	IC50	nM	140.0
303472	17684333	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(CN3CCC(O)CC3)cc(-c3cc(F)c(CO)c(F)c3)c12		CHEMBL3667986	=	IC50	nM	65.0	CHEMBL5311	Homo sapiens	IC50	nM	65.0
303473	17684334	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(CN3CCC(O)C3)cc(-c3cc(F)c(CO)c(F)c3)c12		CHEMBL3667987	=	IC50	nM	30.0	CHEMBL5311	Homo sapiens	IC50	nM	30.0
303474	17684335	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(CN3CCCC(O)C3)cc(-c3cc(F)c(CO)c(F)c3)c12		CHEMBL3667988	=	IC50	nM	70.0	CHEMBL5311	Homo sapiens	IC50	nM	70.0
303475	17684336	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	CCc1cc(-c2cc([C@H]3CC[C@H](O)CC3)n3ncnc(N)c23)cc(F)c1CO		CHEMBL3667989	=	IC50	nM	170.0	CHEMBL5311	Homo sapiens	IC50	nM	170.0
303476	17684337	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	COc1cc(-c2cc([C@H]3CC[C@H](O)CC3)n3ncnc(N)c23)cc(F)c1CO		CHEMBL3667990	=	IC50	nM	1.0	CHEMBL5311	Homo sapiens	IC50	nM	1.0
303477	17684338	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	COc1cc(-c2cc(C3CCCNC3)n3ncnc(N)c23)cc(F)c1CO		CHEMBL3667991	=	IC50	nM	2.0	CHEMBL5311	Homo sapiens	IC50	nM	2.0
303478	17684339	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Cc1cc(-c2cc(C3CCCNC3)n3ncnc(N)c23)cc(F)c1CO		CHEMBL3667992	=	IC50	nM	4.0	CHEMBL5311	Homo sapiens	IC50	nM	4.0
303479	17684340	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Cc1cc(-c2cc(C3CCNC3)n3ncnc(N)c23)cc(F)c1CO		CHEMBL3667993	=	IC50	nM	4.0	CHEMBL5311	Homo sapiens	IC50	nM	4.0
303480	17684341	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	Nc1ncnn2c(C3(O)CCCCC3)cc(-c3cc(F)c(CO)c(F)c3)c12		CHEMBL3667994	=	IC50	nM	15.0	CHEMBL5311	Homo sapiens	IC50	nM	15.0
303481	17684342	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	NCc1nc(-c2cc(-c3cc(F)c(CO)c(F)c3)c3c(N)ncnn23)cs1		CHEMBL3667995	=	IC50	nM	4.1	CHEMBL5311	Homo sapiens	IC50	nM	4.1
303482	17684343	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	COc1cc(-c2cc(C(O)C3CC3)n3ncnc(N)c23)ccc1CO		CHEMBL3667999	=	IC50	nM	3.2	CHEMBL5311	Homo sapiens	IC50	nM	3.2
303483	17684344	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	COc1cc(-c2cc(C(O)C3CC3)n3ncnc(N)c23)ccc1CO		CHEMBL3667999	=	IC50	nM	3.5	CHEMBL5311	Homo sapiens	IC50	nM	3.5
303484	17684345	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	COc1cc(-c2cc(C(O)C3CC3)n3ncnc(N)c23)ccc1CO		CHEMBL3667999	=	IC50	nM	1.2	CHEMBL5311	Homo sapiens	IC50	nM	1.2
303485	17684346	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	CC(C)c1cc(-c2cc(F)c(CO)c(F)c2)c2c(N)ncnn12		CHEMBL3668000	=	IC50	nM	1.9	CHEMBL5311	Homo sapiens	IC50	nM	1.9
303486	17684347	CHEMBL3706168	Flashplate Assay: In vitro enzyme inhibition using scintillation of incorporated radio label (flashplate assay). Test compounds diluted in DMSO are mixed with a suitable substrate / co-substrate (here: bio- tinylated a-casein and 3P-ATP) in a corresponding assay buffer. Addition of the enzyme of interest (here: ALKl kinase) starts the enzyme reaction. The enzyme-catalyzed incorporation of radio label into the substrate is measured via scintillation. Incorporated radio label is separated from free radio label via specific binding of the biotinylated substrate to strepavidin-coated microliter plates (flashplates) and concomitant washing steps. The scintillation signal intensity (counts per minutes, cpm) is proportional to the enzyme activity. Enzyme inhibition results in a decreased signal intensity. IC50 values of the test compounds are determined by cpm-versus-[I] plots. Reaction buffer: Reaction buffer contains 50 mM Tris pi I 8.0 (Sigma), 1 mM MnCi2 (Sigma), 0.01% Nonidet P40 (Fluka).	B	CC(O)c1cc(-c2cc(F)c(CO)c(F)c2)c2c(N)ncnn12		CHEMBL3668001	=	IC50	nM	3.8	CHEMBL5311	Homo sapiens	IC50	nM	3.8
303487	17684348	CHEMBL3706167	"Radiometric Assay: ALKl (Invitrogen, Carlsbad, CA, USA) kinase activity was measured at ProQinase GmbH ( Freiburg. Germany) in a radiometric assay using gamma-33P-ATP and casein (Sigma, St. Louis, MO, USA) as substrate in 96-weli PerkinElmer FlashPlates (Boston, MA, USA). The compounds were tested at 10 concentrations in the range of 1 x 10""4 M to 3 x 10""9 M in a total volume of 50 ul with a finalDMSO concentration of 1 % each. The assay components were mixed in the order: 20 ul assay buffer (70 mM HEPES-NaOH, pi I 7.5. 3 mM MgCl2, 3 mM MnCl2, 2uM sodium orthovanadate, 1.2 mM DTT); - 5ul gamma-33P-ATP (1.0ug/50ug in water, approx. 6 x10E+5 cpm per well); 5 ul test compound solution (in 10% DMSO);10 ul substrate (200 ug/ml, 1.0ug/50ml final concentration) / enzyme (4 ug/ml, 20 ng/50ul = 5.5 nM final concentration) solution (1 : 1 mixture)."	B	Nc1ncnn2c1c(-c1cc(F)c(CO)c(F)c1)cc2[C@H]1CC[C@H](O)CC1		CHEMBL3667969	=	IC50	nM	6.7	CHEMBL5311	Homo sapiens	IC50	nM	6.7
303488	17684349	CHEMBL3706167	"Radiometric Assay: ALKl (Invitrogen, Carlsbad, CA, USA) kinase activity was measured at ProQinase GmbH ( Freiburg. Germany) in a radiometric assay using gamma-33P-ATP and casein (Sigma, St. Louis, MO, USA) as substrate in 96-weli PerkinElmer FlashPlates (Boston, MA, USA). The compounds were tested at 10 concentrations in the range of 1 x 10""4 M to 3 x 10""9 M in a total volume of 50 ul with a finalDMSO concentration of 1 % each. The assay components were mixed in the order: 20 ul assay buffer (70 mM HEPES-NaOH, pi I 7.5. 3 mM MgCl2, 3 mM MnCl2, 2uM sodium orthovanadate, 1.2 mM DTT); - 5ul gamma-33P-ATP (1.0ug/50ug in water, approx. 6 x10E+5 cpm per well); 5 ul test compound solution (in 10% DMSO);10 ul substrate (200 ug/ml, 1.0ug/50ml final concentration) / enzyme (4 ug/ml, 20 ng/50ul = 5.5 nM final concentration) solution (1 : 1 mixture)."	B	Nc1ncnn2c([C@@H]3CCCNC3)cc(-c3cc(F)c(CO)c(F)c3)c12		CHEMBL3667973	=	IC50	nM	3.0	CHEMBL5311	Homo sapiens	IC50	nM	3.0
303489	17684350	CHEMBL3706167	"Radiometric Assay: ALKl (Invitrogen, Carlsbad, CA, USA) kinase activity was measured at ProQinase GmbH ( Freiburg. Germany) in a radiometric assay using gamma-33P-ATP and casein (Sigma, St. Louis, MO, USA) as substrate in 96-weli PerkinElmer FlashPlates (Boston, MA, USA). The compounds were tested at 10 concentrations in the range of 1 x 10""4 M to 3 x 10""9 M in a total volume of 50 ul with a finalDMSO concentration of 1 % each. The assay components were mixed in the order: 20 ul assay buffer (70 mM HEPES-NaOH, pi I 7.5. 3 mM MgCl2, 3 mM MnCl2, 2uM sodium orthovanadate, 1.2 mM DTT); - 5ul gamma-33P-ATP (1.0ug/50ug in water, approx. 6 x10E+5 cpm per well); 5 ul test compound solution (in 10% DMSO);10 ul substrate (200 ug/ml, 1.0ug/50ml final concentration) / enzyme (4 ug/ml, 20 ng/50ul = 5.5 nM final concentration) solution (1 : 1 mixture)."	B	CCc1cc(-c2cc([C@H]3CC[C@H](O)CC3)n3ncnc(N)c23)cc(F)c1CO		CHEMBL3667989	=	IC50	nM	124.0	CHEMBL5311	Homo sapiens	IC50	nM	124.0
303490	17684351	CHEMBL3706167	"Radiometric Assay: ALKl (Invitrogen, Carlsbad, CA, USA) kinase activity was measured at ProQinase GmbH ( Freiburg. Germany) in a radiometric assay using gamma-33P-ATP and casein (Sigma, St. Louis, MO, USA) as substrate in 96-weli PerkinElmer FlashPlates (Boston, MA, USA). The compounds were tested at 10 concentrations in the range of 1 x 10""4 M to 3 x 10""9 M in a total volume of 50 ul with a finalDMSO concentration of 1 % each. The assay components were mixed in the order: 20 ul assay buffer (70 mM HEPES-NaOH, pi I 7.5. 3 mM MgCl2, 3 mM MnCl2, 2uM sodium orthovanadate, 1.2 mM DTT); - 5ul gamma-33P-ATP (1.0ug/50ug in water, approx. 6 x10E+5 cpm per well); 5 ul test compound solution (in 10% DMSO);10 ul substrate (200 ug/ml, 1.0ug/50ml final concentration) / enzyme (4 ug/ml, 20 ng/50ul = 5.5 nM final concentration) solution (1 : 1 mixture)."	B	Nc1ncnn2c(C3CCNC3)cc(-c3cc(F)c(CO)c(F)c3)c12		CHEMBL3667970	=	IC50	nM	6.9	CHEMBL5311	Homo sapiens	IC50	nM	6.9
303491	17684352	CHEMBL3706167	"Radiometric Assay: ALKl (Invitrogen, Carlsbad, CA, USA) kinase activity was measured at ProQinase GmbH ( Freiburg. Germany) in a radiometric assay using gamma-33P-ATP and casein (Sigma, St. Louis, MO, USA) as substrate in 96-weli PerkinElmer FlashPlates (Boston, MA, USA). The compounds were tested at 10 concentrations in the range of 1 x 10""4 M to 3 x 10""9 M in a total volume of 50 ul with a finalDMSO concentration of 1 % each. The assay components were mixed in the order: 20 ul assay buffer (70 mM HEPES-NaOH, pi I 7.5. 3 mM MgCl2, 3 mM MnCl2, 2uM sodium orthovanadate, 1.2 mM DTT); - 5ul gamma-33P-ATP (1.0ug/50ug in water, approx. 6 x10E+5 cpm per well); 5 ul test compound solution (in 10% DMSO);10 ul substrate (200 ug/ml, 1.0ug/50ml final concentration) / enzyme (4 ug/ml, 20 ng/50ul = 5.5 nM final concentration) solution (1 : 1 mixture)."	B	Nc1ncnn2c(C3CCNC3)cc(-c3cc(F)c(CO)c(F)c3)c12		CHEMBL3667970	=	IC50	nM	21.0	CHEMBL5311	Homo sapiens	IC50	nM	21.0
303492	17684353	CHEMBL3706167	"Radiometric Assay: ALKl (Invitrogen, Carlsbad, CA, USA) kinase activity was measured at ProQinase GmbH ( Freiburg. Germany) in a radiometric assay using gamma-33P-ATP and casein (Sigma, St. Louis, MO, USA) as substrate in 96-weli PerkinElmer FlashPlates (Boston, MA, USA). The compounds were tested at 10 concentrations in the range of 1 x 10""4 M to 3 x 10""9 M in a total volume of 50 ul with a finalDMSO concentration of 1 % each. The assay components were mixed in the order: 20 ul assay buffer (70 mM HEPES-NaOH, pi I 7.5. 3 mM MgCl2, 3 mM MnCl2, 2uM sodium orthovanadate, 1.2 mM DTT); - 5ul gamma-33P-ATP (1.0ug/50ug in water, approx. 6 x10E+5 cpm per well); 5 ul test compound solution (in 10% DMSO);10 ul substrate (200 ug/ml, 1.0ug/50ml final concentration) / enzyme (4 ug/ml, 20 ng/50ul = 5.5 nM final concentration) solution (1 : 1 mixture)."	B	CCc1cc(-c2cc(C3CCNC3)n3ncnc(N)c23)cc(F)c1CO		CHEMBL3667996	<	IC50	nM	3.0	CHEMBL5311	Homo sapiens	IC50	nM	3.0
303493	17684354	CHEMBL3706167	"Radiometric Assay: ALKl (Invitrogen, Carlsbad, CA, USA) kinase activity was measured at ProQinase GmbH ( Freiburg. Germany) in a radiometric assay using gamma-33P-ATP and casein (Sigma, St. Louis, MO, USA) as substrate in 96-weli PerkinElmer FlashPlates (Boston, MA, USA). The compounds were tested at 10 concentrations in the range of 1 x 10""4 M to 3 x 10""9 M in a total volume of 50 ul with a finalDMSO concentration of 1 % each. The assay components were mixed in the order: 20 ul assay buffer (70 mM HEPES-NaOH, pi I 7.5. 3 mM MgCl2, 3 mM MnCl2, 2uM sodium orthovanadate, 1.2 mM DTT); - 5ul gamma-33P-ATP (1.0ug/50ug in water, approx. 6 x10E+5 cpm per well); 5 ul test compound solution (in 10% DMSO);10 ul substrate (200 ug/ml, 1.0ug/50ml final concentration) / enzyme (4 ug/ml, 20 ng/50ul = 5.5 nM final concentration) solution (1 : 1 mixture)."	B	CCc1cc(-c2cc(C3CCCNC3)n3ncnc(N)c23)cc(F)c1CO		CHEMBL3667997	=	IC50	nM	4.0	CHEMBL5311	Homo sapiens	IC50	nM	4.0
303494	17684355	CHEMBL3706167	"Radiometric Assay: ALKl (Invitrogen, Carlsbad, CA, USA) kinase activity was measured at ProQinase GmbH ( Freiburg. Germany) in a radiometric assay using gamma-33P-ATP and casein (Sigma, St. Louis, MO, USA) as substrate in 96-weli PerkinElmer FlashPlates (Boston, MA, USA). The compounds were tested at 10 concentrations in the range of 1 x 10""4 M to 3 x 10""9 M in a total volume of 50 ul with a finalDMSO concentration of 1 % each. The assay components were mixed in the order: 20 ul assay buffer (70 mM HEPES-NaOH, pi I 7.5. 3 mM MgCl2, 3 mM MnCl2, 2uM sodium orthovanadate, 1.2 mM DTT); - 5ul gamma-33P-ATP (1.0ug/50ug in water, approx. 6 x10E+5 cpm per well); 5 ul test compound solution (in 10% DMSO);10 ul substrate (200 ug/ml, 1.0ug/50ml final concentration) / enzyme (4 ug/ml, 20 ng/50ul = 5.5 nM final concentration) solution (1 : 1 mixture)."	B	CCc1cc(-c2cc(C(O)C3CC3)n3ncnc(N)c23)cc(F)c1CO		CHEMBL3667998	=	IC50	nM	5.7	CHEMBL5311	Homo sapiens	IC50	nM	5.7
Inactive	17881347	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Active	17881348	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	=	Kd	nM	15.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	15.0
Inactive	17881349	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881350	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881351	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881352	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881353	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881354	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881355	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881356	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881357	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881358	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881359	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881360	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881361	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881362	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881363	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881364	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881365	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881366	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881367	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881368	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881369	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881370	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881371	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881372	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881373	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17881374	CHEMBL3991616	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL5311	Homo sapiens	Kd apparent	nM	30000.0
	17982154	CHEMBL3998833	Inhibition of human ALK1 at 1 uM using casein as substrate in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	COc1cc(O)c2c(c1)CCC[C@H](O)[C@H](O)C(=O)CCC[C@H](C)OC2=O		CHEMBL4099337	>	Inhibition	%	80.0	CHEMBL5311	Homo sapiens	INH	%	80.0
	17982161	CHEMBL3998827	Inhibition of human ALK1 using casein as substrate in presence of [gamma-33P]-ATP by scintillation counting method	B	COc1cc(O)c2c(c1)CCC[C@H](O)[C@H](O)C(=O)CCC[C@H](C)OC2=O		CHEMBL4099337	=	IC50	nM	62.0	CHEMBL5311	Homo sapiens	IC50	uM	0.062
	17982162	CHEMBL3998827	Inhibition of human ALK1 using casein as substrate in presence of [gamma-33P]-ATP by scintillation counting method	B	COc1cc(O)c2c(c1)CCC[C@H](O)[C@H](O)[C@H](O)CCC[C@H](C)OC2=O		CHEMBL4072401	=	IC50	nM	1785.0	CHEMBL5311	Homo sapiens	IC50	uM	1.785
	17982163	CHEMBL3998827	Inhibition of human ALK1 using casein as substrate in presence of [gamma-33P]-ATP by scintillation counting method	B	COc1cc(O)c2c(c1)CCC[C@H](O)[C@H](O)[C@@H](O)CCC[C@H](C)OC2=O		CHEMBL4061009	=	IC50	nM	770.0	CHEMBL5311	Homo sapiens	IC50	uM	0.77
	17982164	CHEMBL3998827	Inhibition of human ALK1 using casein as substrate in presence of [gamma-33P]-ATP by scintillation counting method	B	C=C1CCC[C@H](C)OC(=O)c2c(O)cc(OC)cc2CCC[C@H](O)[C@@H]1O		CHEMBL4082892	=	IC50	nM	1256.0	CHEMBL5311	Homo sapiens	IC50	uM	1.256
	17982165	CHEMBL3998827	Inhibition of human ALK1 using casein as substrate in presence of [gamma-33P]-ATP by scintillation counting method	B	COc1cc(O)c2c(c1)CCC[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O		CHEMBL2012519	=	IC50	nM	125.0	CHEMBL5311	Homo sapiens	IC50	uM	0.125
Active	17982186	CHEMBL3998835	Inhibition of ALK1 in human A375 cells assessed as decrease in MEK1/2 phosphorylation at 1 uM by western blot analysis	B	COc1cc(O)c2c(c1)CCC[C@H](O)[C@H](O)C(=O)CCC[C@H](C)OC2=O		CHEMBL4099337		Inhibition	%		CHEMBL5311	Homo sapiens	INH		
	17982187	CHEMBL3998836	Inhibition of human ALK1 at 10 uM using casein as substrate in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	COc1cc(O)c2c(c1)CCC[C@H](O)[C@H](O)C(=O)NCC[C@H](C)OC2=O		CHEMBL4071615	<	Inhibition	%	40.0	CHEMBL5311	Homo sapiens	INH	%	40.0
	17982205	CHEMBL3998846	Inhibition of human ALK1 using casein as substrate in presence of 10 uM ATP by radiometric kinase assay	B	COc1cc(O)c2c(c1)CCC[C@H](O)[C@H](O)C(=O)CCC[C@H](C)OC2=O		CHEMBL4099337	=	IC50	nM	62.0	CHEMBL5311	Homo sapiens	IC50	nM	62.0
	17982206	CHEMBL3998846	Inhibition of human ALK1 using casein as substrate in presence of 10 uM ATP by radiometric kinase assay	B	c1ccc2c(-c3cnn4cc(-c5ccc(N6CCNCC6)cc5)cnc34)ccnc2c1		CHEMBL513147	=	IC50	nM	11.13	CHEMBL5311	Homo sapiens	IC50	nM	11.13
	17982217	CHEMBL3998851	Inhibition of human ALK1 using casein as substrate in presence of 200 uM ATP by radiometric kinase assay	B	COc1cc(O)c2c(c1)CCC[C@H](O)[C@H](O)C(=O)CCC[C@H](C)OC2=O		CHEMBL4099337	=	IC50	nM	1213.0	CHEMBL5311	Homo sapiens	IC50	nM	1213.0
Active	17982235	CHEMBL3998866	Inhibition of ALK1 in human A375 cells assessed as decrease in MEK1/2 phosphorylation at 0.1 to 10 uM by western blot analysis	B	COc1cc(O)c2c(c1)CCC[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O		CHEMBL2012519		Inhibition	%		CHEMBL5311	Homo sapiens	INH		
	18099884	CHEMBL4021791	Inhibition of ALK1 (unknown origin)	B	Cc1ccc(CNc2nc(N)nc3[nH]c4cc(C)c(O)cc4c23)cc1		CHEMBL4098682	>	IC50	nM	100000.0	CHEMBL5311	Homo sapiens	IC50	uM	100.0
	18114491	CHEMBL4025003	Inhibition of wild-type human ACVRL1 (L164 to Q503 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	89.0	CHEMBL5311	Homo sapiens	Activity	%	89.0
	18203393	CHEMBL4043814	Inhibition of wild-type human ACVRL1 (L164 to Q503 residues) expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	100.0	CHEMBL5311	Homo sapiens	Activity	%	100.0
	18218021	CHEMBL4047090	Inhibition of ALK1 (unknown origin) at 10 uM using [33P]-ATP after 20 to 40 mins by scintillation counting method	B	Cc1ccc(NC(=O)c2c(N=Cc3ccc4ccccc4c3)c(C#N)c3n2CCC3)cc1	Outside typical range	CHEMBL4079032	=	Inhibition	%	-18.0	CHEMBL5311	Homo sapiens	INH	%	-18.0
	18218022	CHEMBL4047090	Inhibition of ALK1 (unknown origin) at 10 uM using [33P]-ATP after 20 to 40 mins by scintillation counting method	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Inhibition	%	14.0	CHEMBL5311	Homo sapiens	INH	%	14.0
	18253729	CHEMBL4055149	Inhibition of wild-type human ALK1 (L164 to Q503 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	100.0	CHEMBL5311	Homo sapiens	Activity	%	100.0
	18253730	CHEMBL4055149	Inhibition of wild-type human ALK1 (L164 to Q503 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	100.0	CHEMBL5311	Homo sapiens	Activity	%	100.0
	18440069	CHEMBL4156893	Binding affinity to wild-type human ACVRL1 (L164 to Q503 residues) expressed in bacterial expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	100.0	CHEMBL5311	Homo sapiens	Activity	%	100.0
	18484509	CHEMBL4185672	Binding affinity to wild-type human ACVRL1 (L164 to Q503 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	90.0	CHEMBL5311	Homo sapiens	Activity	%	90.0
	18485112	CHEMBL4185672	Binding affinity to wild-type human ACVRL1 (L164 to Q503 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	92.0	CHEMBL5311	Homo sapiens	Activity	%	92.0
	18507906	CHEMBL4190856	Inhibition of recombinant human ALK1 (142 to end residues) at 1 uM using casein as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1	Outside typical range	CHEMBL4207014	=	Inhibition	%	-48.0	CHEMBL5311	Homo sapiens	INH	%	-48.0
	18655648	CHEMBL4230572	Binding affinity to wild-type human ACVRL1 (L164 to Q503 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	100.0	CHEMBL5311	Homo sapiens	Activity	%	100.0
	18674994	CHEMBL4235472	Binding affinity to human ALK1 by KdELECT assay	B	Cc1nc2ccc(-c3ccnc4ccccc34)c(C)c2c(=O)[nH]1		CHEMBL4247751	=	Kd	nM	41.0	CHEMBL5311	Homo sapiens	Kd	nM	41.0
	18674995	CHEMBL4235472	Binding affinity to human ALK1 by KdELECT assay	B	O=c1c2cc(-c3ccnc4ccccc34)ccc2ncn1-c1ccc(N2CCOCC2)cc1		CHEMBL4244382	=	Kd	nM	420.0	CHEMBL5311	Homo sapiens	Kd	nM	420.0
Active	18674998	CHEMBL4235469	Inhibition of human ALK1 at 1 uM by scanEDGE assay	B	Cc1nc2ccc(-c3ccnc4ccccc34)c(C)c2c(=O)[nH]1		CHEMBL4247751		Inhibition	%		CHEMBL5311	Homo sapiens	INH		
	18751366	CHEMBL4263983	Inhibition of ALK1 (unknown origin) using Ulight topo IIa (Thr 1342) peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr by TR-FRET analysis	B	CC(c1ccc(-c2cnc3c(-c4ccc(S(N)(=O)=O)c5ccccc45)cnn3c2)cc1)N1CCCC1		CHEMBL4283638	=	IC50	nM	51.0	CHEMBL5311	Homo sapiens	IC50	nM	51.0
	18752053	CHEMBL4264161	Binding affinity to wild-type human ACVRL1 (L164 to Q503 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	100.0	CHEMBL5311	Homo sapiens	Activity	%	100.0
	18857788	CHEMBL4307678	Binding affinity to wild-type human ACVRL1 (L164 to Q503 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	100.0	CHEMBL5311	Homo sapiens	Activity	%	100.0
	18892554	CHEMBL4314718	Inhibition of recombinant human ALK1 (142 to end residues) assessed as residual activity at 10 uM using casein as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	98.0	CHEMBL5311	Homo sapiens	Activity	%	98.0
	18895021	CHEMBL4315503	Inhibition of recombinant human N-terminal GST-tagged ALK1 (144 to end residues) expressed in baculovirus infected Sf9 insect cells assessed as enzyme activity incubated for 15 mins by [gamma-33]ATP based scintillation counting method relative to control	B	CC(C)C/C=N/c1c(C#N)c2n(c1C(=O)Nc1ccc(Br)cc1)CCC2		CHEMBL4592358	=	Activity	%	-5.0	CHEMBL5311	Homo sapiens	Activity	%	-5.0
	18895040	CHEMBL4315503	Inhibition of recombinant human N-terminal GST-tagged ALK1 (144 to end residues) expressed in baculovirus infected Sf9 insect cells assessed as enzyme activity incubated for 15 mins by [gamma-33]ATP based scintillation counting method relative to control	B	CC/C=N/c1c(C#N)c2n(c1C(=O)Nc1ccccc1)CCC2		CHEMBL4527978	=	Activity	%	4.0	CHEMBL5311	Homo sapiens	Activity	%	4.0
	18895059	CHEMBL4315503	Inhibition of recombinant human N-terminal GST-tagged ALK1 (144 to end residues) expressed in baculovirus infected Sf9 insect cells assessed as enzyme activity incubated for 15 mins by [gamma-33]ATP based scintillation counting method relative to control	B	CCC1SCC(=O)N1c1c(C#N)c2n(c1C(=O)Nc1ccccc1)CCC2		CHEMBL4471323	=	Activity	%	11.0	CHEMBL5311	Homo sapiens	Activity	%	11.0
	18895078	CHEMBL4315503	Inhibition of recombinant human N-terminal GST-tagged ALK1 (144 to end residues) expressed in baculovirus infected Sf9 insect cells assessed as enzyme activity incubated for 15 mins by [gamma-33]ATP based scintillation counting method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Activity	%	14.0	CHEMBL5311	Homo sapiens	Activity	%	14.0
	18937699	CHEMBL4327579	Inhibition of human ALK1 assessed as residual activity at 1 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	106.88	CHEMBL5311	Homo sapiens	Activity	%	106.88
	18937700	CHEMBL4327579	Inhibition of human ALK1 assessed as residual activity at 1 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	104.91	CHEMBL5311	Homo sapiens	Activity	%	104.91
	18938420	CHEMBL4327940	Inhibition of human ALK1 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	B	c1ccc2c(-c3cnn4cc(-c5ccc(N6CCNCC6)cc5)cnc34)ccnc2c1		CHEMBL513147	<	Activity	%	65.0	CHEMBL5311	Homo sapiens	Activity	%	65.0
Not Determined	18938785	CHEMBL4328304	Inhibition of human ALK1 using casein as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978		IC50			CHEMBL5311	Homo sapiens	IC50		
	18938786	CHEMBL4328304	Inhibition of human ALK1 using casein as substrate by [gamma-33P]-ATP assay	B	c1ccc2c(-c3cnn4cc(-c5ccc(N6CCNCC6)cc5)cnc34)ccnc2c1		CHEMBL513147	=	IC50	nM	19.6	CHEMBL5311	Homo sapiens	IC50	10'-8M	1.96
	18958691	CHEMBL4333272	Binding affinity to wild-type human ACVRL1 (L164 to Q503 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	100.0	CHEMBL5311	Homo sapiens	Activity	%	100.0
	18964054	CHEMBL4334961	Inhibition of recombinant human ALK1 (142 to end residues) assessed as residual activity at 1 uM using casein as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	99.0	CHEMBL5311	Homo sapiens	Activity	%	99.0
	18964055	CHEMBL4334961	Inhibition of recombinant human ALK1 (142 to end residues) assessed as residual activity at 1 uM using casein as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	95.0	CHEMBL5311	Homo sapiens	Activity	%	95.0
	18971778	CHEMBL4336788	Inhibition of recombinant human ALK1 (142 to end residues) assessed as residual activity at 10 uM using casein as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	78.0	CHEMBL5311	Homo sapiens	Activity	%	78.0
Not Active	19039904	CHEMBL4351738	Inhibition of recombinant human ALK1 (142 to end residues) at 10 uM using casein as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL5311	Homo sapiens	INH		
Active	19041005	CHEMBL4352266	Inhibition of human ALK1 at 10 uM using casein as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL5311	Homo sapiens	INH		
	19059449	CHEMBL4357750	Binding affinity to wild-type human ACVRL1 (L164 to Q503 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	100.0	CHEMBL5311	Homo sapiens	Activity	%	100.0
	19090022	CHEMBL4365596	Inhibition of wild-type human ACVRL1 (L164 to Q503 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	100.0	CHEMBL5311	Homo sapiens	Activity	%	100.0
	19091808	CHEMBL4366282	Inhibition of human ALK1 at 100 nM using casein as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	-8.35	CHEMBL5311	Homo sapiens	INH	%	-8.35
	19111750	CHEMBL4370593	Inhibition of ALK1 (unknown origin) using Kemptide as substrate at 1 uM after 60 mins by ADP-Glo luminescence assay relative to control	B	Cc1cc(Nc2nc(Nc3ccc(C(=O)NC4CC(C)(C)N([O])C(C)(C)C4)cc3)ncc2F)no1		CHEMBL4522901	=	Inhibition	%	39.0	CHEMBL5311	Homo sapiens	INH	%	39.0
	19111751	CHEMBL4370593	Inhibition of ALK1 (unknown origin) using Kemptide as substrate at 1 uM after 60 mins by ADP-Glo luminescence assay relative to control	B	CCCCOC(=O)Cc1cc(Nc2nc(Nc3ccc(C(=O)NC4CC(C)(C)N([O])C(C)(C)C4)cc3)ncc2F)n[nH]1		CHEMBL4443086	=	Inhibition	%	33.5	CHEMBL5311	Homo sapiens	INH	%	33.5
	19144609	CHEMBL4377625	Inhibition of recombinant human ALK1 (142 to end residues) at 1 uM using casein as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	-5.0	CHEMBL5311	Homo sapiens	INH	%	-5.0
	19147739	CHEMBL4379135	Inhibition of human recombinant ALK1 (142 to end residues) using casein as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL5311	Homo sapiens	IC50	uM	10.0
	19159277	CHEMBL4382381	Binding affinity to wild-type human ACVRL1 (L164 to Q503 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	30.0	CHEMBL5311	Homo sapiens	Activity	%	30.0
	19191248	CHEMBL4389577	Inhibition of wild-type human ACVRL1 (L164 to Q503 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	100.0	CHEMBL5311	Homo sapiens	INH	%	100.0
	19191730	CHEMBL4389100	Inhibition of wild-type human ACVRL1 (L164 to Q503 residues) expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	100.0	CHEMBL5311	Homo sapiens	INH	%	100.0
	19200019	CHEMBL4391203	Binding affinity to wild-type human ACVRL1 (L164 to Q503 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	100.0	CHEMBL5311	Homo sapiens	Activity	%	100.0
	19266305	CHEMBL4405255	Inhibition of wild-type human ACVRL1 (L164 to Q503 residues) expressed in bacterial expression system B14at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL5311	Homo sapiens	INH	%	50.0
Active	19271764	CHEMBL4406770	Inhibition of ALK1 (unknown origin) at 1 uM	B	COc1cc(-c2cncc(-c3ccc(N4CCN(C)CC4)cc3)c2C)cc(F)c1C(N)=O		CHEMBL4575655		Inhibition	%		CHEMBL5311	Homo sapiens	INH		
Active	19271765	CHEMBL4406770	Inhibition of ALK1 (unknown origin) at 1 uM	B	COc1cc(-c2cncc(-c3ccc(N4CCN(C(C)C)CC4)cc3)c2C)cc(F)c1C(N)=O		CHEMBL4548795		Inhibition	%		CHEMBL5311	Homo sapiens	INH		
Active	19271766	CHEMBL4406770	Inhibition of ALK1 (unknown origin) at 1 uM	B	COc1cc(-c2cncc(-c3ccc(N4C[C@H](C)N(C)[C@H](C)C4)cc3)c2C)cc(F)c1C(N)=O		CHEMBL4434717		Inhibition	%		CHEMBL5311	Homo sapiens	INH		
	19275925	CHEMBL4407928	Inhibition of recombinant human ALK1 (142 to end residues) at 1 uM using casein as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	58.0	CHEMBL5311	Homo sapiens	INH	%	58.0
	20690527	CHEMBL4625382	Inhibition of ALK1 (unknown origin) assessed as enzyme remaining activity at 10 uM relative to control	B	NS(=O)(=O)c1cc(Nc2cc(Oc3cn(C4CC4)nc3C3CCOCC3)ccn2)ccc1F		CHEMBL4646566	=	Activity	%	2.0	CHEMBL5311	Homo sapiens	Activity	%	2.0
	20694073	CHEMBL4626188	Inhibition of human ALK1 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assay	A	COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2C)cc(OC)c1OC		CHEMBL4517408	=	IC50	nM	15.0	CHEMBL5311	Homo sapiens	IC50	nM	15.0
	22423841	CHEMBL4674496	Inhibition of human ALK1 using casein as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	27.03	CHEMBL5311	Homo sapiens	Activity	%	27.03
	22423842	CHEMBL4674496	Inhibition of human ALK1 using casein as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	21.75	CHEMBL5311	Homo sapiens	Activity	%	21.75
	22844322	CHEMBL4721185	Inhibition of human ALK1 assessed as residual activity using casein as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	67.07	CHEMBL5311	Homo sapiens	Activity	%	67.07
	22844615	CHEMBL4721290	Inhibition of wild-type human partial length ACVRL1 (L164 to Q503 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	74.02	CHEMBL5311	Homo sapiens	Activity	%	74.02
	22884255	CHEMBL4727753	Inhibition of human ALK1 using casein as substrate by [gamma-33P]-ATP assay	B	Cc1cc(-c2cnc3cc(-c4ccc(N5CCNCC5)cc4)ccn23)c2ccccc2n1		CHEMBL4740381	=	IC50	nM	39.1	CHEMBL5311	Homo sapiens	IC50	nM	39.1
	22884256	CHEMBL4727753	Inhibition of human ALK1 using casein as substrate by [gamma-33P]-ATP assay	B	Cc1cc(-c2cnc3cc(-c4ccc(N5CCNCC5)cc4)ccn23)c2cc(F)ccc2n1		CHEMBL4788859	=	IC50	nM	166.3	CHEMBL5311	Homo sapiens	IC50	nM	166.3
	22884257	CHEMBL4727753	Inhibition of human ALK1 using casein as substrate by [gamma-33P]-ATP assay	B	Cc1cc(-c2cnc3cc(-c4ccc(N5CCNCC5)cc4)ccn23)c2cc(F)cc(F)c2n1		CHEMBL4786529	=	IC50	nM	308.8	CHEMBL5311	Homo sapiens	IC50	nM	308.8
	22884258	CHEMBL4727753	Inhibition of human ALK1 using casein as substrate by [gamma-33P]-ATP assay	B	Cc1cc(-c2cnc3cc(-c4ccc(C5CNCCN5)cc4)ccn23)c2ccccc2n1		CHEMBL4742906	<	IC50	nM	5.0	CHEMBL5311	Homo sapiens	IC50	nM	5.0
	22884259	CHEMBL4727753	Inhibition of human ALK1 using casein as substrate by [gamma-33P]-ATP assay	B	Cc1cc(-c2cnc3cc(-c4ccc(C5CNCCN5)cc4)ccn23)c2cc(F)cc(F)c2n1		CHEMBL4778971	=	IC50	nM	89.2	CHEMBL5311	Homo sapiens	IC50	nM	89.2
	22886503	CHEMBL4728240	Binding affinity to ACVRL1 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay	B	CC(=O)c1cccc(-c2cnc3ccc(NCC4CC4)nn23)c1		CHEMBL200528	>	Delta Tm	degrees C	6.0	CHEMBL5311	Homo sapiens	deltaTm	degrees C	6.0
	22952747	CHEMBL4766684	Inhibition of recombinant human ALK1 (142 to end residues) assessed as residual activity at 10 uM using casein as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	94.0	CHEMBL5311	Homo sapiens	Activity	%	94.0
	23122435	CHEMBL4804786	Inhibition of human ACVRL1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	93.0	CHEMBL5311	Homo sapiens	Activity	%	93.0
	23123130	CHEMBL4805374	Inhibition of human ACVRL1 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	99.0	CHEMBL5311	Homo sapiens	Activity	%	99.0
	23123755	CHEMBL4805999	Inhibition of DNA-tagged human ACVRL1 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	100.0	CHEMBL5311	Homo sapiens	Activity	%	100.0
	23124350	CHEMBL4806391	Inhibition of human ACVRL1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	99.0	CHEMBL5311	Homo sapiens	Activity	%	99.0
	23124351	CHEMBL4806391	Inhibition of human ACVRL1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	100.0	CHEMBL5311	Homo sapiens	Activity	%	100.0
	23127798	CHEMBL4807741	Inhibition of ACVRL1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	<	Activity	%	25.0	CHEMBL5311	Homo sapiens	Activity	%	25.0
	23127799	CHEMBL4807741	Inhibition of ACVRL1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	=	Activity	%	25.0	CHEMBL5311	Homo sapiens	Activity	%	25.0
	23127800	CHEMBL4807741	Inhibition of ACVRL1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Activity	%	25.0	CHEMBL5311	Homo sapiens	Activity	%	25.0
	23248264	CHEMBL4830441	Inhibition of human ALK1 using casein as substrate assessed as enzyme activity incubated for 2 hrs by [gamma-33P]-ATP assay relative to control	B	CC(C)c1c2cc(-c3ccnc(Nc4ccc5c(N6CCN(C)CC6)ccnc5c4)n3)ccc2nn1C		CHEMBL4856177	<	Activity	%	20.0	CHEMBL5311	Homo sapiens	Activity	%	20.0
Not Active	23317270	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	76.0	CHEMBL5311	Homo sapiens	% Control	%	76.0
Not Active	23317738	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	98.0	CHEMBL5311	Homo sapiens	% Control	%	98.0
Not Active	23318412	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23318888	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23319528	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23320000	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	99.4	CHEMBL5311	Homo sapiens	% Control	%	99.4
Not Active	23320678	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	95.0	CHEMBL5311	Homo sapiens	% Control	%	95.0
Not Active	23321146	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23321776	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	99.0	CHEMBL5311	Homo sapiens	% Control	%	99.0
Not Active	23322244	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23322933	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	97.0	CHEMBL5311	Homo sapiens	% Control	%	97.0
Not Active	23323401	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	90.0	CHEMBL5311	Homo sapiens	% Control	%	90.0
Not Active	23324255	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	79.0	CHEMBL5311	Homo sapiens	% Control	%	79.0
Not Active	23324890	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	85.0	CHEMBL5311	Homo sapiens	% Control	%	85.0
Not Active	23325358	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	97.0	CHEMBL5311	Homo sapiens	% Control	%	97.0
Not Active	23326005	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	99.0	CHEMBL5311	Homo sapiens	% Control	%	99.0
Slightly Active	23326473	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	45.0	CHEMBL5311	Homo sapiens	% Control	%	45.0
Not Active	23327173	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	98.0	CHEMBL5311	Homo sapiens	% Control	%	98.0
Not Active	23327641	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	72.0	CHEMBL5311	Homo sapiens	% Control	%	72.0
Not Active	23328228	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23328696	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	94.0	CHEMBL5311	Homo sapiens	% Control	%	94.0
Not Active	23329241	CHEMBL4880948	ALK1(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	118.0	CHEMBL5311	Homo sapiens	% residual kinase activity	%	118.0
Not Active	23329642	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	94.0	CHEMBL5311	Homo sapiens	% Control	%	94.0
Not Active	23330110	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	91.0	CHEMBL5311	Homo sapiens	% Control	%	91.0
Not Active	23330866	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23331334	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23331921	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	78.9	CHEMBL5311	Homo sapiens	% Control	%	78.9
Not Active	23332389	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23333105	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	71.7	CHEMBL5311	Homo sapiens	% Control	%	71.7
Not Active	23333744	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	87.0	CHEMBL5311	Homo sapiens	% Control	%	87.0
Not Active	23334212	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23335191	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23335659	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	93.0	CHEMBL5311	Homo sapiens	% Control	%	93.0
Not Active	23336286	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23336754	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23337835	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	84.0	CHEMBL5311	Homo sapiens	% Control	%	84.0
Not Active	23338303	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	86.0	CHEMBL5311	Homo sapiens	% Control	%	86.0
Not Active	23338915	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23339383	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23340020	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23340488	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	96.0	CHEMBL5311	Homo sapiens	% Control	%	96.0
Not Active	23341145	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23341613	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23342229	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	77.0	CHEMBL5311	Homo sapiens	% Control	%	77.0
Not Active	23342697	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23343327	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	68.0	CHEMBL5311	Homo sapiens	% Control	%	68.0
Not Active	23343795	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	97.0	CHEMBL5311	Homo sapiens	% Control	%	97.0
Not Active	23344433	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23345006	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	97.0	CHEMBL5311	Homo sapiens	% Control	%	97.0
Not Active	23345474	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	84.0	CHEMBL5311	Homo sapiens	% Control	%	84.0
Not Active	23346051	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	66.5	CHEMBL5311	Homo sapiens	% Control	%	66.5
Not Active	23346520	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23347130	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	90.9	CHEMBL5311	Homo sapiens	% Control	%	90.9
Not Active	23347611	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	92.3	CHEMBL5311	Homo sapiens	% Control	%	92.3
Not Active	23348190	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23348658	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23349245	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23349863	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23350331	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23350936	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	88.0	CHEMBL5311	Homo sapiens	% Control	%	88.0
Not Active	23351404	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23352428	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	94.0	CHEMBL5311	Homo sapiens	% Control	%	94.0
Not Active	23352896	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	63.0	CHEMBL5311	Homo sapiens	% Control	%	63.0
Not Active	23353778	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23354246	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23354978	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23355446	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	99.0	CHEMBL5311	Homo sapiens	% Control	%	99.0
Not Active	23356082	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23356550	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23357159	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23357806	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	77.0	CHEMBL5311	Homo sapiens	% Control	%	77.0
Not Active	23358274	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23358860	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23359458	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	93.0	CHEMBL5311	Homo sapiens	% Control	%	93.0
Not Active	23359926	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	80.0	CHEMBL5311	Homo sapiens	% Control	%	80.0
Not Active	23360511	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	87.0	CHEMBL5311	Homo sapiens	% Control	%	87.0
Not Active	23360979	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	86.0	CHEMBL5311	Homo sapiens	% Control	%	86.0
Not Active	23361552	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23362088	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23362556	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	99.0	CHEMBL5311	Homo sapiens	% Control	%	99.0
Not Active	23364198	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	72.0	CHEMBL5311	Homo sapiens	% Control	%	72.0
Not Active	23364666	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	77.0	CHEMBL5311	Homo sapiens	% Control	%	77.0
Not Active	23365405	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	82.0	CHEMBL5311	Homo sapiens	% Control	%	82.0
Not Active	23365948	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	88.0	CHEMBL5311	Homo sapiens	% Control	%	88.0
Not Active	23366538	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23367006	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23367466	CHEMBL4883819	ACV-RL1 ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	105.0	CHEMBL5311	Homo sapiens	% Residual activity with Skepinone-L	%	105.0
Not Active	23367884	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	99.0	CHEMBL5311	Homo sapiens	% Control	%	99.0
Not Active	23368352	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	81.0	CHEMBL5311	Homo sapiens	% Control	%	81.0
Not Active	23368951	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23369419	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	94.0	CHEMBL5311	Homo sapiens	% Control	%	94.0
Not Active	23369966	CHEMBL4884213	ALK1(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	138.0	CHEMBL5311	Homo sapiens	% residual kinase activity	%	138.0
Not Active	23370387	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	75.0	CHEMBL5311	Homo sapiens	% Control	%	75.0
Not Active	23370855	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	97.0	CHEMBL5311	Homo sapiens	% Control	%	97.0
Not Active	23371664	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	96.0	CHEMBL5311	Homo sapiens	% Control	%	96.0
Not Active	23372132	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	97.0	CHEMBL5311	Homo sapiens	% Control	%	97.0
	23372654	CHEMBL4884619	ALK1(ACL1LGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL5311	Homo sapiens	pIC50		6.0
	23373063	CHEMBL4884910	ALK1(ACL1LGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL5311	Homo sapiens	pIC50		6.0
	23373424	CHEMBL4885201	ALK1(ACL1LGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL5311	Homo sapiens	pIC50		6.0
Not Active	23375559	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	93.0	CHEMBL5311	Homo sapiens	% Control	%	93.0
Not Active	23376027	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23376605	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	99.0	CHEMBL5311	Homo sapiens	% Control	%	99.0
Not Active	23377074	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	70.0	CHEMBL5311	Homo sapiens	% Control	%	70.0
Not Active	23377932	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	72.0	CHEMBL5311	Homo sapiens	% Control	%	72.0
Not Active	23378400	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	78.0	CHEMBL5311	Homo sapiens	% Control	%	78.0
Not Active	23379567	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	95.0	CHEMBL5311	Homo sapiens	% Control	%	95.0
Not Active	23380035	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23380729	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	93.0	CHEMBL5311	Homo sapiens	% Control	%	93.0
Not Active	23381377	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23381845	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23382469	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23382937	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23383569	CHEMBL4887229	ACVRL1 (ALK1) Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	64.0	CHEMBL5311	Homo sapiens	% Ctrl	%	64.0
Not Active	23384173	CHEMBL4887768	ALK1(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	-6.17	CHEMBL5311	Homo sapiens	% inhibition	%	-6.17
Not Active	23384852	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
Not Active	23385319	CHEMBL4879576	KinomeScan assay: inhibition of ACVRL1	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	100.0	CHEMBL5311	Homo sapiens	% Control	%	100.0
